Epithelial ovarian cancer cell lines spontaneously derived from solid tumors of patient diagnosed with clear-cell carcinoma suubtype
| Inventor | Institute |
|---|---|
| Anne-Marie Mes-Masson and Diane Provencher | Centre Hospitalier de Luniversité de Montréal |
| SKU: | 161786 |
|---|---|
| Product description: | Epithelial ovarian cancer cell lines spontaneously derived from solid tumors of patient diagnosed with clear-cell carcinoma suubtype. Sample was taken from the right ovary. Cell line produces tumors in mice upon SC injection |
| Alternate name: | TOV-3392D |
| Gender: | Female |
| CRISPR: | No |
| Production details: | Established using the Scrape method where tumor tissue was scraped into a 100mm plate with complete OSE medium and maintained for 40 days with medium replaced weekly. |
| Additional notes: | Patient 3392 had previous personal history of breast cancer and was naive to ovarian cancer treatment but received prior chemotherapy for breast cancer. Patient was age 42 at diagnosis and har prior history of breast cancer. Treatment included 5-fluorouracil, epirubicin, cyclo-phosphamide, radiotherapy, and trastuzumab. Sampling was done during 2007. |
| Cellosaurus ID: | CVCL_A1SS |
| Receptors of note: | No |
| Cat. #: | 161786 |
|---|---|
| Cancer types: | Ovarian cancer |
| Research Fields: | Cancer |
| Organism: | Human |
| Tissue: | Derived from solid tumor of patient diagnosed with epithelial ovarian cancer with a clear cell carcinoma subtype |
| Gender: | Female |
| Morphology: | Characteristic flat epithelial morphology, grew in dense clusters, and gained little confluence |
| Growth properties: | Adherent |
| Primary citation: | Sauriol A et al. 2020. Cancers. 12(8):2222. PMID: 32784519 |
| Shipping conditions: | Dry Ice |
|---|---|
| Growth medium: | OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin |
| Temperature: | 37° C |
| Atmosphere: | Low oxygen conditions of 7% O2 and 5% CO2 |
| References: |
Gaia-Oltean et al. 2021. Exp Ther Med. 21(3):243. PMID: 33603851 Canals Hernaez et al. 2020. J Immunother Cancer. 8(2):e001128. PMID: 33243933 Borzdzi?owska et al. 2022. Biomedicines. 11 10(5):1116. PMID: 35625852 Meng et al. 2023. J Anim Sci. 3 101:skad215. PMID: 37351870 Koni et al. 2020. Int J Mol Sci. 18 21(20):7697. PMID: 33080952 |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.